Indiana University receives $5M grant to expand breast cancer diagnosis, care in Kenya

OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill

The Trump administration has a fight on its hands as it pushes forward with a plan to exert greater political control over government funding of science.

ARPA-H awards up to $160M to advance personalized curative medicines for rare genetic diseases

The Advanced Research Projects Agency for Health, an agency within the U.S. Department of Health and Human Services, announced the teams for the Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines (THRIVE) program—a critical investment toward bringing new treatments to patients faster and curing rare genetic pediatric diseases.

July 10, 2026

Vol.52 No.27

In Brief

Cancer Research Institute issues 93 awards totaling $37 million

The Cancer Research Institute announced its largest-ever annual grantmaking—93 awards totaling $37 million—as federal funding for cancer research remains uncertain.

July 10, 2026

Vol.52 No.27

Clinical Roundup

Young women diagnosed with breast cancer within three years of childbirth may face more aggressive disease, UCLA study finds

Breast cancers diagnosed during the first three years after childbirth, particularly within the first year, may be biologically more aggressive than similar cancers in women who have never given birth, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

July 10, 2026

Vol.52 No.27

Clinical Roundup

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

For people at high risk of developing breast cancer, yearly mammograms may not be enough to detect tumors early. To make earlier diagnosis easier, a Massachusetts Institute of Technology team has developed portable detectors based on ultrasound, which could be used much more frequently. The team reports that they have improved the resolution of the images produced by their system, making it easier to spot potential tumors, as well as cysts and microcalcifications.

July 10, 2026

Vol.52 No.27

Clinical Roundup

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

MammaPrint + BluePrint can help identify a subset of patients with hormone receptor positive, HER2-negative early-stage breast cancer most likely to benefit from anthracycline-based chemotherapy, according to the results of the prospective FLEX Study (NCT03053193).

July 02, 2026

Vol.52 No.26

Indiana University receives $5M grant to expand breast cancer diagnosis, care in Kenya

YOU MAY BE INTERESTED IN

OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill

ARPA-H awards up to $160M to advance personalized curative medicines for rare genetic diseases

Cancer Research Institute issues 93 awards totaling $37 million

Young women diagnosed with breast cancer within three years of childbirth may face more aggressive disease, UCLA study finds

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

Renew today!

Subscriber content

Never miss an issue!

Login